GeoVax Labs to Present at Major Investor Conferences
GeoVax Labs, Inc. (Nasdaq: GOVX) is a leading biotechnology company dedicated to creating innovative immunotherapies and vaccines for both cancers and infectious diseases. As the company gears up for two important investor conferences, excitement is building. David Dodd, the Chairman and CEO, will be at the forefront of these presentations.
H.C. Wainwright 26th Annual Global Investment Conference
GeoVax is scheduled to present at the H.C. Wainwright 26th Annual Global Investment Conference. During this session, David Dodd will provide valuable insights into the company's recent progress and future plans. The presentation is set for September 9, 2024, at 7:00 a.m. ET, and will take place at a prominent venue in New York City, fostering an engaging environment for networking and idea exchange.
One-on-One Meetings
In addition to the main presentation, senior management from GeoVax will conduct one-on-one meetings with registered attendees. Those interested in discussing the company’s initiatives can reach out through the conference portal or contact GeoVax directly at info@geovax.com.
Emerging Growth Conference
After the H.C. Wainwright event, GeoVax will participate in the Emerging Growth Conference on September 25, 2024, at 2:55 p.m. ET. This event will be held virtually, making it accessible to a wider audience. During this conference, David Dodd will continue to share updates about the company's corporate developments and progress in its clinical programs.
Webcast Available
A webcast link will be made available for those who wish to follow the presentations remotely, ensuring that investors can stay updated on the significant initiatives GeoVax is pursuing within the biotechnology sector.
About GeoVax
GeoVax Labs, Inc. is at the forefront of biotechnology, focusing on developing innovative vaccines that address some of the most urgent infectious diseases worldwide. In addition to its work in infectious diseases, the company is also advancing therapies for solid tumor cancers. One of its key programs is GEO-CM04S1, an advanced COVID-19 vaccine currently undergoing multiple Phase 2 clinical trials. Recently, GeoVax secured a BARDA-funded contract to support a major Phase 2b clinical trial involving 10,000 participants to evaluate the efficacy of GEO-CM04S1 against an approved COVID-19 vaccine.
Moreover, GEO-CM04S1 is being assessed in specific patient populations, including those with hematologic cancers who have limited options with existing vaccines. In the realm of cancer therapy, GeoVax is developing a novel oncolytic therapy named Gedeptin®, which is currently being tested in a multicenter Phase 1/2 trial for advanced head and neck cancers. With a strong intellectual property portfolio backing its efforts, GeoVax holds extensive rights to its technologies and products.
Company Contact Details
Company Contact: info@geovax.com | 678-384-7220
Investor Relations Contact: austin.murtagh@precisionaq.com | 212-698-8696
Media Contact: sr@roberts-communications.com | 202-779-0929
Frequently Asked Questions
What is GeoVax Labs, Inc. known for?
GeoVax is recognized for its development of groundbreaking immunotherapies and vaccines that target infectious diseases and cancers.
Who will represent GeoVax at the investor conferences?
David Dodd, the Chairman and CEO of GeoVax, will be the representative presenting at both conferences.
When are the upcoming investor events?
The upcoming events are set for September 9 and September 25, 2024.
How can I attend the presentations?
The presentations will be accessible via webcast, and one-on-one meetings can be scheduled through the conference portals.
What is the primary focus of GeoVax’s clinical trials?
The clinical trials primarily focus on advancing a next-generation COVID-19 vaccine and innovative therapies for various types of cancers.
![aelf and Gaia Partner for the Groundbreaking Hello [AI] Event](/images/blog/ihnews-aelf%20and%20Gaia%20Partner%20for%20the%20Groundbreaking%20Hello%20%5BAI%5D%20Event.jpg)
